84206b838d
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
- Source: inbox/queue/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md - Domain: health - Claims: 0, Entities: 1 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
50 lines
No EOL
2.5 KiB
Markdown
50 lines
No EOL
2.5 KiB
Markdown
# EVOKE/EVOKE+ Trials
|
|
|
|
**Type:** Phase 3 clinical trials
|
|
**Sponsor:** Novo Nordisk
|
|
**Intervention:** Oral semaglutide 14mg (flexible dose)
|
|
**Indication:** Early-stage symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia with confirmed amyloid positivity)
|
|
**Status:** Failed (2026)
|
|
|
|
## Trial Design
|
|
|
|
- **Design:** Two parallel Phase 3, double-blind, placebo-controlled trials
|
|
- **Population:** n=3,808 total, ages 55-85
|
|
- **Duration:** 104 weeks primary endpoint, 156 weeks extended follow-up
|
|
- **Primary endpoints:** Cognitive and global decline measures
|
|
|
|
## Results
|
|
|
|
**Primary endpoints:** Not met in either trial. Semaglutide did not demonstrate superiority to placebo in slowing cognitive or global decline.
|
|
|
|
**Secondary endpoints:**
|
|
- No delay in time to progression to dementia (MCI subgroup, pooled analysis)
|
|
- **Biomarker findings:** Up to 10% reduction in CSF core AD biomarkers (amyloid, tau)
|
|
- Significant reductions in CSF neuroinflammation markers
|
|
- **Critical gap:** Biomarker improvements did not translate to clinical benefit
|
|
|
|
## Scientific Interpretation
|
|
|
|
The biomarker-clinical benefit dissociation suggests three possible explanations:
|
|
1. Dose insufficient to produce clinical effect despite biomarker change
|
|
2. Treatment window too late (early symptomatic disease already past intervention point)
|
|
3. Neuroinflammation/AD pathobiology not rate-limiting in this population
|
|
|
|
## Implications
|
|
|
|
**For GLP-1 CNS expansion:** Establishes mechanism specificity boundary. Semaglutide shows efficacy in addiction (VTA dopamine pathways) but not neurodegeneration (amyloid/tau pathways), indicating GLP-1 CNS effects are pathway-specific rather than universally neuroprotective.
|
|
|
|
**For Alzheimer's drug development:** Adds to evidence that biomarker improvement (even in core AD pathology markers) does not guarantee clinical benefit, raising questions about surrogate endpoint validity.
|
|
|
|
**For prevention vs. treatment:** May indicate GLP-1 has preventive rather than therapeutic value in neurodegeneration, requiring different trial design in at-risk populations.
|
|
|
|
## Timeline
|
|
|
|
- **2026-04-15** — Results published in The Lancet
|
|
- **2026-04** — Novo Nordisk announces discontinuation of 1-year extension periods for both trials
|
|
|
|
## Sources
|
|
|
|
- The Lancet (2026): "Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials"
|
|
- Alzheimer's Drug Discovery Foundation analysis
|
|
- NeurologyLive coverage |